Health Care [ 4/12 ] | Biotechnology [ 20/74 ]
NASDAQ | Common Stock
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024.
The company was incorporated in 2015 and is based in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 29, 24 | -0.18 Increased by +10.00% | 0.07 Decreased by -366.67% |
| Jul 23, 24 | -0.06 Decreased by -128.57% | -0.07 Increased by +14.29% |
| Apr 23, 24 | -0.25 Decreased by -38.89% | -0.16 Decreased by -56.25% |
| Feb 28, 24 | 0.35 Increased by +483.33% | -0.14 Increased by +350.00% |
| Oct 31, 23 | -0.20 Decreased by -106.29% | -0.17 Decreased by -17.65% |
| Jul 25, 23 | 0.21 Increased by +172.41% | -0.17 Increased by +223.53% |
| May 2, 23 | -0.18 Increased by +50.00% | -0.21 Increased by +14.29% |
| Feb 28, 23 | 0.06 Increased by +111.32% | -0.23 Increased by +126.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 112.21 M Increased by +67.37% | -12.69 M Increased by +8.39% | Decreased by -11.31% Increased by +45.26% |
| Jun 30, 24 | 108.63 M Increased by +51.99% | -3.91 M Decreased by -126.10% | Decreased by -3.60% Decreased by -117.17% |
| Mar 31, 24 | 79.86 M Increased by +65.18% | -17.70 M Decreased by -44.29% | Decreased by -22.17% Increased by +12.65% |
| Dec 31, 23 | 83.39 M Increased by +34.76% | 25.24 M Increased by +465.73% | Increased by +30.26% Increased by +319.80% |
| Sep 30, 23 | 67.05 M Decreased by -32.37% | -13.86 M Decreased by -106.18% | Decreased by -20.66% Decreased by -109.14% |
| Jun 30, 23 | 71.47 M Increased by +164.99% | 14.97 M Increased by +174.93% | Increased by +20.95% Increased by +128.28% |
| Mar 31, 23 | 48.34 M Increased by +50.19% | -12.27 M Increased by +51.33% | Decreased by -25.38% Increased by +67.59% |
| Dec 31, 22 | 61.88 M Increased by +230.14% | 4.46 M Increased by +112.28% | Increased by +7.21% Increased by +103.72% |